Back to Saturn V Capital Management LP
Saturn V Capital Management LP
Q3 2026 13F filing
Updated 6 days ago24 disclosed positions worth $683.1M
Portfolio value
$683.1M
Total holdings
24
New positions
0
Closed positions
0
Increased
0
Decreased
0
Turnover
—
Filed
2026-11-16
Full holdings
Every line item disclosed in Q3 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | A AMYLYX PHARMACEUTICALS INC | $130.1M | 4.47M | 19.05% | — |
| 2 | A ABIVAX SA | $52.4M | 529.3K | 7.67% | — |
| 3 | ? N/A IMMIX BIOPHARMA INC | $48.5M | 4.66M | 7.10% | — |
| 4 | P PHARVARIS N V | $44.2M | 1.39M | 6.47% | — |
| 5 | P VAXCYTE INC | $43.9M | 772.3K | 6.43% | — |
| 6 | C CELCUITY INC | $40.9M | 513.8K | 5.98% | — |
| 7 | I DISC MEDICINE INC | $40.1M | 612.7K | 5.87% | — |
| 8 | C CANDEL THERAPEUTICS INC | $36.3M | 3.48M | 5.31% | — |
| 9 | J JAZZ PHARMACEUTICALS PLC | $34.8M | 150.3K | 5.10% | — |
| 10 | M MONOPAR THERAPEUTICS INC | $24.9M | 312.4K | 3.64% | — |
| 11 | V VIR BIOTECHNOLOGY INC | $22.8M | 2.04M | 3.34% | — |
| 12 | T TREVI THERAPEUTICS INC | $22.5M | 1.57M | 3.30% | — |
| 13 | ? N/A X4 PHARMACEUTICALS INC | $21.4M | 7.37M | 3.13% | — |
| 14 | A ALUMIS INC | $21.1M | 2.86M | 3.09% | — |
| 15 | S SAGIMET BIOSCIENCES INC | $19.8M | 2.00M | 2.90% | — |
| 16 | D DYNE THERAPEUTICS INC | $13.5M | 837.2K | 1.97% | — |
| 17 | A ALTO NEUROSCIENCE INC | $13.2M | 518.1K | 1.94% | — |
| 18 | R ULTRAGENYX PHARMACEUTICAL IN | $11.4M | 758.8K | 1.67% | — |
| 19 | Z ZURA BIO LTD | $8.5M | 2.03M | 1.24% | — |
| 20 | I INHIBIKASE THERAPEUTICS INC | $8M | 3.87M | 1.16% | — |
| 21 | O OCULIS HOLDING AG | $7.9M | 847.4K | 1.16% | — |
| 22 | E ERASCA INC | $7.5M | 514.3K | 1.10% | — |
| 23 | L LATIGO BIOTHERAPEUTICS INC | $5M | 300.4K | 0.73% | — |
| 24 | M SATELLOS BIOSCIENCE INC | $4.4M | 516.8K | 0.64% | — |